Production and regulatory issues for theranostics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38821100.
- Also identified by DOI 10.1016/S1470-2045(24)00041-X and PMC identifier 11325260.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Theranostics has become a major area of innovation and progress in cancer care over the last decade. In view of the introduction of approved therapeutics in neuroendocrine tumours and prostate cancer in the last 10 years, the ability to provide access to these treatments has emerged as a key factor in ensuring global benefits from this cancer therapy approach. In this Series paper we explore the issues that affect access to and availability of theranostic radiopharmaceuticals, including supply and regulatory issues that might affect the availability of theranostic treatments for patients with cancer.
Medical subject headings
- Radiopharmaceuticals
- Theranostic Nanomedicine